Sacituzumab govitecan targets TROP2 on tumor cells, is internalized, and releases SN-38, which inhibits topoisomerase I to cause DNA damage and apoptosis. Topoisomerase I is the payload’s enzymatic target, not the ADC’s binding target, so Topoisomerase I–expressing cells are not specifically targeted (bystander killing may occur).